Company news
Krystal Biotech, Inc. (NASDAQ:KRYS) news
Krystal Biotech, Inc. news releases on 6ix. Latest, Nov 7, 2022: Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
Press releases — page 3
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
November 6, 2022
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 28, 2022
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
September 20, 2022
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 7, 2022
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
August 17, 2022
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
August 7, 2022
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
July 31, 2022
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
July 5, 2022
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
June 21, 2022
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
June 6, 2022
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
May 18, 2022
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
May 8, 2022
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
May 2, 2022
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
April 10, 2022
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
March 27, 2022
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
March 25, 2022
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
March 23, 2022
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
March 17, 2022
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
March 14, 2022
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
February 27, 2022
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
February 23, 2022
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
January 17, 2022
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
November 29, 2021
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
November 28, 2021
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
November 28, 2021
Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
November 18, 2021
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
November 7, 2021
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
October 25, 2021
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
October 18, 2021
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
October 13, 2021
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)
October 11, 2021
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
September 30, 2021
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
September 28, 2021
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
September 14, 2021
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
September 8, 2021
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
August 8, 2021
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
June 30, 2021
Krystal Biotech to Participate in Upcoming Investor Conferences
June 2, 2021
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress
May 9, 2021
Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
May 2, 2021
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
April 26, 2021
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
April 25, 2021
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
April 18, 2021
Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
March 29, 2021
Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications
March 23, 2021
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
February 28, 2021
Krystal Biotech to Present at the Cowen 41st Annual Health Care Conference
February 22, 2021
Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock
February 1, 2021
Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock
February 1, 2021